Lidoflazine

Lidoflazine
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	C08EX01 (WHO) ;
Identifiers
	IUPAC name 2-[4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl]-N-(2,6-dimethylphenyl)acetamide;
CAS Number	3416-26-0 ;
PubChem CID	3926;
ChemSpider	3789 ;
UNII	J4ZHN3HBTE;
KEGG	D04733 ;
CompTox Dashboard (EPA)	DTXSID6045377 ;
ECHA InfoCard	100.020.285
Chemical and physical data
Formula	C30H35F2N3O
Molar mass	491.627 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	159 to 161 °C (318 to 322 °F)
Solubility in water	Almost insoluble in water(<0.01%); Very soluble in chloroform(>50%); mg/mL (20 °C)
	SMILES CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F;
	InChI InChI=1S/C30H35F2N3O/c1-22-5-3-6-23(2)30(22)33-29(36)21-35-19-17-34(18-20-35)16-4-7-28(24-8-12-26(31)13-9-24)25-10-14-27(32)15-11-25/h3,5-6,8-15,28H,4,7,16-21H2,1-2H3,(H,33,36) ; Key:ZBIAKUMOEKILTF-UHFFFAOYSA-N ;
	(what is this?) (verify)

Lidoflazine is a piperazine calcium channel blocker. It is a coronary vasodilator with some antiarrhythmic action.^[1] Lidoflazine was discovered at Janssen Pharmaceutica in 1964.

^ Schaper WK, Xhoneux R, Jageneau AH, Janssen PA (May 1966). "The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator". The Journal of Pharmacology and Experimental Therapeutics. 152 (2): 265–274. doi:10.1016/S0022-3565(25)27319-0. PMID 5944369.

[JPET-1] Schaper WK, Xhoneux R, Jageneau AH, Janssen PA (May 1966). "The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator". The Journal of Pharmacology and Experimental Therapeutics. 152 (2): 265–274. doi:10.1016/S0022-3565(25)27319-0. PMID 5944369.

[1]